Jazz Pharmaceuticals PLC at Evercore ISI HealthCONx Conference Transcript
Thank you guys for being here. Pleasure to have Jazz management join us before we kick things off, maybe I'll turn it over to you Renee to get us going.
Sure. Yes, happy to. Thanks for having us and thank you all for joining us. Just a few housekeeping items. We will be making forward-looking statements today. Please see our website and SEC filings for more information about our business. Should we make reference to financial guidance. We're not updating or reiterating today. All of our guidance is as of Q3 earnings call on November 8. And should we make reference to non-GAAP measures. You can find full reconciliations on our website.
So turning to the business. I'm quite energized by where we are today. The business has been through a complete transformation over the last several years. In 2020, we had about $2.4 billion in revenues, 75% of that was coming from a single product.
Our pipeline was more nascent and R&D capabilities more limited. Looking at where we
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |